Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 8:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1921–1944 of 4,244 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Study Product Clear all

Conditions: Emotional Dysregulation
Interventions: N-Acetyl Cysteine (NAC), Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 6 Years to 12 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2030
U.S. locations: 2
States / cities: Boston, Massachusetts • Cambridge, Massachusetts

Conditions: Wet Macular Degeneration
Interventions: KSI-301, Aflibercept, Sham Procedure; Drug · Other
Lead sponsor: Kodiak Sciences Inc; Industry
Eligibility: 50 Years and older
Enrollment: 559 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 59
States / cities: Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 53 more

Conditions: Chronic Pressure Ulcers
Interventions: PuraPly® Antimicrobial Wound Matrix, SOC for Pressure Ulcers; Device · Other
Lead sponsor: Organogenesis; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Lake Success, New York • Mineola, New York

Conditions: X Linked Myotubular Myopathy
Interventions: ApoTamox 10mg, Placebo; Drug
Lead sponsor: James Dowling; Other
Eligibility: 6 Months and older · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: Chicago, Illinois • Rockville, Maryland

Conditions: Ventricular Dysfunction, Left, Major Adverse Cardiac Events
Interventions: EGHEM; Procedure
Lead sponsor: University of Nebraska; Other
Eligibility: 70 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Intrahepatic Cholestasis of Pregnancy
Interventions: Volixibat, Placebo; Drug
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 7
States / cities: Birmingham, Alabama • New Haven, Connecticut • Miami, Florida + 4 more

Conditions: Type 2 Diabetes Mellitus
Interventions: WB-010, WB-011, Placebo; Other
Lead sponsor: Pendulum Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 5
States / cities: Torrance, California • Tustin, California • Youngstown, Ohio + 2 more

Conditions: Fatigue
Interventions: Active Fatigue Product 1A, Active Fatigue Product 1B, Placebo Fatigue Control 1A, Placebo Fatigue Control 1B; Dietary Supplement
Lead sponsor: Radicle Science; Industry
Eligibility: 40 Years to 105 Years
Enrollment: 1,320 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Del Mar, California

Conditions: Autism Spectrum Disorders
Interventions: Riluzole, placebo; Drug · Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 12 Years to 25 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Opioid-Related Disorders, Opiate Dependence
Interventions: Buprenorphine/naloxone sublingual tablets, Buprenorphine; Drug
Lead sponsor: Orexo AB; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 14
States / cities: Birmingham, Alabama • Haleyville, Alabama • National City, California + 11 more

Conditions: Trigeminal Neuralgia
Interventions: lamotrigine, Placebo; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 15 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Depressive Symptoms, Substance Use
Interventions: Arrowhead Business Group Curriculum, Recreational League Control Condition; Behavioral
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 13 Years to 15 Years
Enrollment: 449 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Whiteriver, Arizona

Conditions: Attention Deficit Hyperactivity Disorder, Dyslexia
Interventions: Atomoxetine, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 10 Years to 16 Years
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 16
States / cities: Irvine, California • Palo Alto, California • San Francisco, California + 13 more

Conditions: Postoperative Pain
Interventions: Ketamine, Placebo; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Alzheimer's Disease, Dementia
Interventions: Drug: EVP-6124, Placebo; Drug
Lead sponsor: FORUM Pharmaceuticals Inc; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 42
States / cities: Tucson, Arizona • Little Rock, Arkansas • Culver City, California + 39 more

Conditions: Atopic Dermatitis
Interventions: Ruxolitinib, Vehicle Cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 64
States / cities: Birmingham, Alabama • Hoover, Alabama • Gilbert, Arizona + 49 more

Conditions: Lung Cancer, Non Small Cell Lung Cancer
Interventions: apricoxib, Placebo, Docetaxel or Pemetrexed; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 12
States / cities: Los Angeles, California • Miami, Florida • Chicago, Illinois + 8 more

Conditions: Cancer
Interventions: Psilocybin, Niacin; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 76 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Sjögrens Disease
Interventions: Abiprubart, Placebo; Drug
Lead sponsor: Kiniksa Pharmaceuticals International, plc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 16
States / cities: Menifee, California • Poway, California • Whittier, California + 13 more

Conditions: Ulcerative Colitis, Inflammatory Bowel Diseases, Autoimmune Diseases
Interventions: ATH-063, Placebo; Drug · Other
Lead sponsor: Athos Therapeutics Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 4
States / cities: Miami, Florida • Tampa, Florida • Roswell, Georgia + 1 more

Conditions: Neuropsychiatric Systemic Lupus Erythematosus, Systemic Lupus Erythematosus (SLE), Cognitive Impairment
Interventions: Placebo, EG-501; Drug
Lead sponsor: Evergreen Therapeutics, Inc.; Industry
Eligibility: 18 Years to 69 Years
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 3
States / cities: Cleveland, Ohio • Nashville, Tennessee • Houston, Texas

Conditions: Healthy Volunteer
Interventions: PHP-303, Placebo; Drug · Other
Lead sponsor: pH Pharma; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Actinic Keratosis
Interventions: Generic Fluorouracil Cream, Carac® (Fluorouracil) Cream, Vehicle Cream; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 422 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 17
States / cities: Fremont, California • Los Angeles, California • San Diego, California + 14 more

Conditions: Post Traumatic Stress Disorder
Interventions: 3,4-Methylenedioxymethamphetamine (MDMA), Placebo, Massed Prolonged Exposure (PE); Drug · Behavioral
Lead sponsor: Emory University; Other
Eligibility: 21 Years to 70 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Atlanta, Georgia

Search by objective public record fields.

The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation

A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.

PuraPly® AM Plus the Standard of Care to Standard of Care Alone for the Management of Stage II-IV Pressure Ulcers.

Tamoxifen Therapy for Myotubular Myopathy

Echo-guided Hemodynamic Management Strategy in Elderly Patients Undergoing Noncardiac Surgery

A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OHANA)

Placebo-Controlled Clinical Nutrition Study of the Safety and Metabolic Effects of Two Medical Foods in Type 2 Diabetes

Radicle Energy™ DNB: A Study Assessing the Impact of Health and Wellness Products on Fatigue and Related Health Outcomes

Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders

Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence

Research Study to Test Safety and Effectiveness of Investigational Drug in Patients With Trigeminal Neuralgia

Evaluation of an Entrepreneurship Program for American-Indian Youth

Treatment of ADHD With Atomoxetine in Children & Adolescents With ADHD & Comorbid Dyslexia

Effect of Postoperative Single Dose of Ketamine on Pain After Mastectomy

Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)

0822GCC: Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer

Psilocybin Cancer Anxiety Study

A Study to Evaluate the Efficacy and Safety of Abiprubart in Participants With Sjögren's Disease

Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)

EG-501 for Cognitive Impairment in Neuropsychiatric SLE (NPSLE): Efficacy and Safety Study

A Study of Safety, Tolerability, and Pharmacokinetics of Single Doses of PHP-303 in Healthy Subjects

Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Keratosis

MDMA-Assisted Massed Exposure Therapy for PTSD